$MLAB

Crennen Lyndsey Elizabeth sold $40K of MLAB

Crennen Lyndsey Elizabeth (CAO) sold 442 shares of MESA LABORATORIES INC /CO/ (MLAB) at $89.50 on 2026-06-22.

Original reporting
SEC EDGAR · Crennen Lyndsey Elizabeth
Published Jun 23, 2026, 5:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MLAB
Neutral
medium confidence
Mentioned
$MLAB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest fact is the CAO’s open-market sale details (442 shares at $89.5020; ~$39.6K total) and post-transaction holdings (2,020 shares).

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but it does not introduce new fundamentals.

03

What to watch

Insider sales are common and often not predictive without accompanying changes in guidance, large-scale selling, or repeated transactions over time.

Relevance 3/10Novelty 5/10Timing: filed 2026-06-23 (after-hours/next session) for a sale dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for MESA Laboratories Inc (MLAB).

Company-level read

Ticker impact

$MLABNeutralMedium confidence
Context

Form 4 shows CAO Lyndsey Elizabeth Crennen sold 442 shares of MESA Laboratories at $89.5020 on 2026-06-22, totaling ~$39.6K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction with modest dollar value and no stated 10b5-1 plan, but it does not include new company fundamentals or guidance.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned personal liquidity needs; absence of a 10b5-1 plan doesn’t necessarily imply bearish expectations.

Key entities

  • MLAB

    MESA Laboratories Inc /CO/; subject of the Form 4 insider transaction.

  • Lyndsey Elizabeth Crennen

    CAO of MESA Laboratories; reported open-market sale of 442 shares.

Related articles

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.